Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
Is there a role for the addition of radiation to preoperative chemoimmunotherapy in NSCLC with limited N2 disease planned for surgery?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?